

Faster, more accurate **gold** analysis

Q4 FY23 - Quarterly Investor Update

27 July 2023

I CHRYSOS

Dirk Treasure, Managing Director and CEO Brett Coventry, CFO



The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) ("Chrysos" or the "Group") and is general background information about Chrysos' current activities as at the date of this presentation. The information is given in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with the Company's other announcements to ASX. Information in this presentation, including forecast financial information, should not be considered advice or a recommendation to current shareholders, investors or potential investors, in relation to holding, purchasing or selling securities in the Company, and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation.

Forward-looking statements

This presentation may contain statements that are, or may be deemed to be, forward-looking statements, for example statements that use words such as "may", "will", "would", "could", "expects", "intends", "anticipates", and other similar words that involve risks and uncertainties. You should not place undue reliance on such forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this document, are expected to take place. No person who has made any forward-looking statements in this document has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this document, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company.

This presentation also contains references to certain intentions, expectations and plans of the Company. These intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ.

This presentation may contain information that has been derived from publicly available sources that have not been independent verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of this information.

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance

To the maximum extent permitted by law, Chrysos, its subsidiaries and their respective officers, employees, agents and consultants, and any other person involved in the preparation of this presentation, disclaim all liability and responsibility, including, without limitation, any liability arising out of fault or negligence, for any direct or indirect loss which may arise from or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

CHRYSOS CORPORATION LIMITED | 3

Financial and operating highlights

Q4 FY23 Unaudited Total Revenue of \$8.6m, reflecting 27% growth on the previous Quarter

\$8.6m

Total Unaudited Q4 FY23 Revenue

- +27% growth on Q3 FY23 (\$6.7m)
- MMAP/AAC Revenue of \$7.8m
- FY23 Prospectus target achieved (\$26.8m)

978k

Samples processed

- Increased 20% on Q3 FY23 (818k)
- 50% growth YoY
- Q4 FY23 utilisation rate of 56% (Full-year average: 56%)

\$53.4m

Cash position¹

- Q4 FY23 Net operating cash outflows of \$0.6m
- Operating cash-flow positive for the full year at \$4.2m
- Well-funded to support PhotonAssay[™] unit growth

49

Contracted units¹

- Contracted unit deployment extends into 2025
- Unit clustering to increase revenue, decrease cost
- Supports manufacturing expansion to 18 units/year

\$702m

Total Contract Value (TCV)

- Converted \$6m of TCV to Revenue (Q3 FY23: \$708m)
- 26% growth YoY
- Long-term annuity-style revenue


20

Deployed units^{1,2}

- Two units deployed in the reporting Quarter
- · Morila, Mali unit redeployment to Bamako under way
- 21st Unit deployment to be achieved Q1 FY24

FY23 Revenue and EBITDA Prospectus Forecasts achieved on an unaudited basis

- 1. As at 30 June 2023
- 2. Deployed units are those units which have been deployed and are generating revenue




Top line momentum continuing

) CHRYSOS CORPORATION

Two new unit deployments in Q4 FY23 and consistent Additional Assay Charges driving revenue growth

Unaudited MMAP, AAC & Other Income



- Minimum Monthly Assay Payments (MMAP) provide predictable and sustainable minimum revenue
 - Q4 FY23 MMAP was \$6.8m, up 18% on Q3 FY23 (\$5.7m)
 - The 20 currently deployed units^{1,2} provide a baseline MMAP of \$2.6m per month, or \$31m per year
 - MMAP revenue continues to increase in line with Chrysos' growing deployed unit base
- Additional Assay Charges (AAC) are linked to utilisation, providing revenue on a per-sample basis where customers exceed MMAP
 - AAC accounted for 12% of Q4 FY23 Total Revenue
- Other income reflects the provision of sample jars and lids to customers which is not expected to continue into FY24

Revenue growth reflects the ongoing performance of deployed units and the installation of two additional units in Q4 FY23

2. Deployed units are those units which have been deployed and are generating revenue

Executing on our global PhotonAssay[™] roll out

) CHRYSOS CORPORATION

Strong and sustainable growth underpinned by long-term annuity-style recurring revenue


20 Units Deployed¹



o Offices & manufacturing ● Regions with PhotonAssay[™] due diligence ● Deployed or Installing

Chrysos continues to roll out contracted units globally


Average Unit Utilisation & Samples Processed



FY23 Utilisation rate 56% compared to Prospectus forecast of 55%

Strong sales pipeline ahead


Continued adoption of PhotonAssay[™] by global laboratories and miners



Example Customers

) CHRYSOS CORPORATION

Total Contract Value^{1,2} (Retiring metric)



\$702m of Total Contract Value committed under existing contracts³

¹ TCV is calculated using foreign exchange rates of AUD:USD 0.73, AUD:CAD 0.94 and AUD:GBP 0.56. The USD and CAD rates are based on the average of the 3-month forward curve from Bloomberg in March 2022, per the Chrysos Prospectus and GBP rates are based on the average of the 3-month forward curve from Bloomberg in May 2022.

² TCV represents the future minimum contracted revenue on PhotonAssay leases (both deployed and committed) that are yet to be invoiced at a point in time, which are subject to the Company's contractual performance obligations and where the Directors consider reasonable certainty exists, may include values associated with exercise of option periods.

CHRYSOS CORPORATION LIMITED | 6

³ As at 30 June 2023

FY24 Guidance

) CHRYSOS CORPORATION

Forecastable revenue model provides reliable visibility



FY24 Guidance:

- FY24 Total Revenue range of \$48m to \$58m, an increase of almost 100% at the midpoint
 - Based on MMAP from installed units and 18 units scheduled for deployment during FY24
 - No provision for consumables supply (jars)
- FY24 EBITDA range of \$7m to \$17m, a substantial uplift on FY23
 - EBITDA range primarily driven by revenue
 - Clustering strategy expected to decrease average unit costs over time
- At least 18 PhotonAssay[™] units forecast to be deployed, bringing the total to a forecast 38 units deployed globally by EOFY 24
 - Supported by enhanced deployment and manufacturing capability
 - Includes expansion into the USA and South America

In summary

Chrysos PhotonAssay[™] rollout continues to gather momentum

- Continued top line growth in Q4 FY23:
 - 27% QoQ increase in Unaudited Total Revenue¹
 - 18% QoQ increase in Minimum Monthly Assay Payments
- FY23 Prospectus targets for Revenue and EBITDA achieved on an unaudited basis
- Operating cash-flow positive for the full year FY23 at \$4.2m
- 49 contracted units:
 - 20 currently deployed and generating revenue
 - Contracted unit deployments support FY24 rollout
- Well-funded for sustained growth with \$53.4m cash-on-hand and \$21.5m in undrawn debt







About Chrysos

Chrysos – revolutionising the global mining industry

) CHRYSOS CORPORATION

Chrysos is a global provider of novel assay services through its proprietary PhotonAssay[™] technology

Disruptive Minerals Analysis Technology


- Developed by CSIRO
- Faster process
- More accurate results
- Reduced sample preparation
- Automated operation
- Lower labour requirements
- Improved workplace OHS
- Better environmental outcomes
- Larger, more representative, sample size

Service and Lease Model with Tier 1 Counterparties

- Units operating commercially since 2018
- Deployed across 3 continents
- Over 5.0m commercial samples processed
- Secure Long-Term Revenue
- Unit deployments contracted out to 2025
- \$702m Total Contract Value
- Upside on revenue via increased unit utilisation
- Annual Return on Invested Capital 47% 82%
- Mosaic of technology patents protects from competition


Industry Accepted Technology Displacing Traditional Fire Assay

- Non-discretionary industry spend
- Total addressable market of 610 units globally
- Used in JORC and NI43-101, ISO17025
- Ability to analyse additional elements to gold
- Exponential growth supported by pre-contracted units



Our commercialisation journey

The outcome of 20+ years of research and development



- SA Premier's Award for Energy & Mining – productivity Improvement category
- KCA Award for Best Research Commercialisation

top 4 global laboratory services providers (ALS, Intertek and SGS)

CHRYSOS CORPORATION

Prime Minister's Award

PhotonAssay[™] team wins Prime Minister's Award for Innovation

The Chrysos Vision



To become the world's leading provider of innovative assay services and technologies



Market Challenge:


Traditional assay techniques are slow, labour intensive, complex, destructive to the assay sample, and involve dangerously high temperatures and toxic chemicals that are hazardous to both operators and the environment.



The Solution: Chrysos PhotonAssay™

- ✓ Provides faster and more accurate assaying
- ✓ Allows real-time delivery of information to support agile decision making
- Rapid decision making helps to improve operational efficiency, recovery and profitability
- Removes hazardous chemicals from the assay process protecting operators and reducing emissions
- ✓ Is non-destructive allowing for repeat testing and comparative analysis
- ✓ The process is **largely automated**, reducing labour requirements and the chance of human error

Fully-quantitative analysis in as little as 2 minutes!



PhotonAssay[™] technology


) CHRYSOS CORPORATION

Best in class gold assaying with measurable benefits over traditionally used methods

PhotonAssay[™] vs. Traditional Fire Assay¹

	Fire Assay	PhotonAssay [™]
Time per sample ²	~3-4 hours	~2-3 minutes 🗸
Sample size	10-50 grams	250-650 grams
CO ₂ per sample	0.91kg	0.455kg 🗸
Hazardous waste per sample	0.31kg	0kg 🗸
Energy use per sample ³	1.3kWh	0.65kWh 🗸
Automation	×	\checkmark

PhotonAssay[™] value proposition



1. Comparison of PhotonAssay[™] and fire assay per Frost & Sullivan industry report


2. Fire assay shown based on the minimum processing time. 24-hours is generally considered rapid turn-around time in practice.

3. Assumes same electricity source is used

Large & unpenetrated TAM


Assay expenditure is a non-discretionary operating cost

Existing PhotonAssay[™] Reach



CHRYSOS CORPORATION

TAM for PhotonAssay[™] Units




Delivering tangible benefits for miners



PhotonAssayTM enables timely decision making and additional gold recovery

The opportunity...

- Each year global miners are estimated to lose >\$2.0 billion worth of recoverable gold
- PhotonAssayTM provides miners with access to real-time data, helping to improve decision making through the value chain
- Enabling the optimisation of processes to generate potential productivity gains



PhotonAssay[™] is embedded in the mining value chain

PhotonAssay [™] Value Add		
Exploration	Fast turnaround for mine planning and scheduling in-pit	
Mine		
ROM	Assay-supported blending between pit & processing	
Crushing		
Stockpile	Stockpile sampling & optimised gold recovery	
Multi-stage concentration	Reduction in process reagents & consumables	
Tailings + Water	Tailings grade	
recovery	monitoring	
Gold room	All samples retained for QA/QC	
Product	Buyer / seller assays	



Denotes PhotonAssay ${}^{\rm TM}$ value add

An environmentally-friendly solution

) CHRYSOS CORPORATION

Substantially better for the environment and significantly safer than fire assay

PhotonAssay[™] has a substantial **positive environmental impact** that will continue to grow in tandem with the uptake of the technology

- ✓ PhotonAssay[™] reduces CO₂ emissions and eliminates leadcontaminated waste
- ✓ Quantifiable benefit
 - 0.455kg of CO₂ reduced per sample (compared to fire assay)
 - 0.31kg of hazardous lead-contaminated waste reduced per sample (compared to fire assay)
- Improved OH&S through the elimination of hazardous chemicals, lead exposure, and ultra-high temperatures used in conventional fire assay
 - Fire assayers require routine blood tests to confirm acceptable levels of lead
 - Fire assayers are routinely rotated through other laboratory tasks to prevent a build-up of lead

LIKE TO TREAD MORE LIGHTLY ON THE PLANET?

Every sample analysed with PhotonAssay ${\tt^{\rm M}}$ means reduced CO_2 emissions and less hazardous waste. To date, we have achieved:

3192.52 tonnes Reduced CO₂ emissions

2151.48 tonnes

Hazardous waste reduction


As at 30 June 2023

High barriers to entry

High barriers to entry supported by global IP rights



Barriers to competitive entry



Clear growth pathway


) CHRYSOS CORPORATION

Clear organic growth plan with potential to expand TAM through additional commodities

Business development pipeline

- A growing global network of laboratory leases BMS Intertek ALS SGS AHK **MSALABS** PhotonAssay[™] unit commitments extend out to 2025 Existing customers offer additional deployment opportunities Growing element applicability A focus on profitability Add-on analyses Concurrent moisture Current / Core PhotonAssay[™] applicability and market focus Gold Silver Copper Potential PhotonAssay[™] applicability and expanded market focus
 - Base metals
 - Rare earths
 - Mineral sands

Growth Trajectory for Installed Units (cumulative)



CHRYSOS CORPORATION LIMITED | 18

Experienced leadership team

) CHRYSOS CORPORATION

Supported by a well respected and tenured board

Senior leadership team



Dirk Treasure Founding CEO & Managing Director

- Metallurgist with a background in both technical and commercial mining aspects spanning 15+ years in the industry
- 7 years in novel metallurgical process development and commercialisation prior to becoming Chrysos' founding CEO



Board of Directors

Rob Adamson

Founder & Chairman

- 20+ years' experience in mining and finance
- Executive Chairman of RFC Ambrian

Kerry Gleeson

Director

- Experienced executive and nonexecutive director in mining and associated industries
- Qualified Australian and English Lawyer: M&A, debt & equity funding & commercialising technology



Brett Coventry Chief Financial Officer

- Experienced in taking high growth technology start-ups from inception through to maturity
- 20 years in various roles encompassing international expansion, capital raising and listing through IPO



Brett Boynton Founding Director

- Co-founder of AI data analytics business and founder of London listed gold exploration technology co.
- 20+ years' investment banking experience in London, New York, Sydney



Ivan Mellado Founding Director

- 20 years' experience in technology commercialisation and development ventures
- Business and Law qualifications; experienced executive and NED



Eric Ford Director

40 years of strategic, management, commercial, operating and engineering experience in resources and energy

Greg Holt Director

 Senior executive with an international career spanning 40 years across logistics, industrial services, mining contracting and engineering industries

Thank you

For more information, please visit chrysoscorp.com or contact us at investors@chrysoscorp.com

